Trapping Moving Targets with Small Molecules
Gregory M. Lee, et al.
Science 324, 213 (2009);
DOI: 10.1126/science.1169378

The following resources related to this article are available online at
www.sciencemag.org (this information is current as of April 9, 2009):

Updated information and services, including high-resolution figures, can be found in the online
version of this article at:
http://www.sciencemag.org/cgi/content/full/324/5924/213

Supporting Online Material can be found at:
http://www.sciencemag.org/cgi/content/full/324/5924/213/DC1

This article cites 39 articles, 8 of which can be accessed for free:
http://www.sciencemag.org/cgi/content/full/324/5924/213#otherarticles

This article appears in the following subject collections:
Biochemistry
http://www.sciencemag.org/cgi/collection/biochem

Information about obtaining reprints of this article or about obtaining permission to reproduce
this article in whole or in part can be found at:
http://www.sciencemag.org/about/permissions.dtl
Trapping Moving Targets with Small Molecules

Gregory M. Lee and Charles S. Craik*

Structure-based drug design traditionally uses static protein models as inspirations for focusing on "active" site targets. Allosteric regulation of biological macromolecules, however, is affected by both conformational and dynamic properties of the protein or protein complex and can potentially lead to more avenues for therapeutic development. We discuss the advantages of searching for molecules that conformationally trap a macromolecule in its inactive state. Although multiple methodologies exist to probe protein dynamics and ligand binding, our current discussion highlights the use of nuclear magnetic resonance spectroscopy in the drug discovery and design process.

Normal biological processes generally rely on a finely tuned network of dynamic macromolecular interactions that allow signals to transfer throughout the cell. Misregulation of these signaling complexes often ends in disease states. For example, misregulated protein-protein interactions lead to unchecked cellular signaling in multiple forms of cancer. In fact, many proteins that are intrinsically unstructured or have domains that fold into regular structural motifs upon binding to their partner proteins can be linked to human diseases (1, 2).

To control the activity of these complexes in a disease state, efforts generally focus on small-molecule ligands that competitively bind to a particular catalytic or active site, using a static model of the complex as a starting point. This method has identified and validated a multitude of viable active-site therapeutics in use today. However, as reflected by the high failure rate of new drug compounds (only an estimated 8% of phase I clinical therapeutics eventually gain Food and Drug Administration approval, at a conserv-ative cost of $800 million per drug), many efforts are unsuccessful and often targets are abandoned once they are deemed undruggable (3). Focusing on active-site inhibitors limits the number of potential sites that can be targeted by therapeutics. Expanding the search for inhibitors that bind beyond the active site, or even at protein complex interfaces, offers "more shots on goal" for a particular target. These allosteric effectors can initiate a cascade of changes that alter macromolecular activity (4–6).

The energetics of macromolecular complexes involve enthalpic and entropic properties that govern activity by influencing the conformational rigidity and flexibility of macromolecules within the complex. The main theories linking allosteric regulation to alterations in protein conformation and dynamics, and ultimately protein function, usually focus on the protein folding or ligand binding free-energy landscape (7). The Monod-Wyman-Changeux (MWC) symmetrical model of allostery states that an unbound, or "apo," target protein exists in an equilibrium that thermodynamically favors one of two distinct conformational states and that ligand binding initiates an interconversion between these two states in a concerted manner (8). Conversely, the Koshland-Nemethy-Filmer (KNF) induced-fit model of allos-tery suggests that conformational changes within the target protein propagate sequentially through the system after ligand binding (9). In other words, the unbound target protein is a static structure, and protein dynamics are induced.

More current theories extend the MWC two-state model and posit that in their apo form, pro-teins sample multiple preexisting conformations, the majority of which are minor populations (10, 11). A dynamic free-energy landscape with shallow energy wells and transition barriers would allow the target protein to sample the conformation appropriate for efficient ligand-binding inter-actions (Fig. 1). Upon ligand binding to a minor populated state, the dynamic free-energy land-scape would alter and shift the equilibrium to favor that bound conformational state (7, 11). The concept of allostericity can be extended to include such conformational trapping, which might shift the equilibrium away from the active state. In some cases, allosteric effects may involve pertur-bations in protein dynamics only in the absence of a conformational change, suggesting that ligand binding can be solely due to alterations in en-tropic factors (12).

Allosteric sites might also display more selectiv-ity than active sites. More important, in con-trast to competitive inhibitors, which generally focus on a single conformational binding state, different allosteric inhibitors could target multiple conformational states. This in turn provides more opportunities to inhibit the same macromolecular target. By targeting multiple sites on a particular macromolecule, rather than focusing on a single active site, allosteric therapeutics would encounter less drug resistance due to mutations within the receptor. Resistance to allosteric inhibitors can also eventually occur, but combination therapy against the same target helps alleviate this situation. An example of this type of combination therapy is found in the highly active antiretroviral treatment drug cocktail for AIDS (13).

Several allosterically active drugs are either on the market or in late clinical testing stages. One example is imatinib (Gleevec), discussed below. Other examples include non-nucleoside inhibitors that target HIV reverse transcriptase (14) and herpesvirus C polymerase (15). These inhibitor classes act by restricting conformational mobility in regions of the enzymes required for catalytic activity. Although preclinical, allosteric inhibitors of caspases (dimeric complexes implicated in inflammation and apoptosis) were shown to trap the enzyme in an inactive zymogen conformational state (16). X-ray crystallography, nuclear magnetic resonance (NMR), and computational studies of HIV protease have shown "closed" and "open" flap conformations, which help regulate substrate access to the catalytic site (17). Inhibitors that restrict the motion of these dynamic flaps have potential for regulating the enzymatic activity of a well-validated target at a nonactive site.

Small-molecule inhibitors may also regulate protein-protein interactions by restricting conformational mobility. Because of the larger and flatter surfaces associated with protein-protein interaction sites, discovering small-molecule compounds that disrupt protein complexes is more difficult than discovering those that bind to a monomeric target with well-defined binding pockets (18). Most protein-protein interactions exhibit nanomolar to millimolar binding affinities, and finding the "high-hanging fruit" that capture dynamic macromolecules in their inactive state remains a pathway of high potential (18, 19). Herpesvirus proteases represent a homodimeric enzyme family, members of which are attractive targets for controlling several human viral pathogens with small-molecule compounds (20). Each monomer contains two flexible helices at the dimer interface undergoing a conformational disorder-to-order transition that is critical for regulating enzymatic activity (21). Small molecules that capture an inactive conformation of the monomer and disrupt dimerization may provide new opportunities to make this previously intractable target druggable.

Although there are several methods to discover inhibitors that target dynamic proteins, NMR is particularly suited to sampling multiple time frames in order to characterize protein motion and is a powerful technique for detecting conformational changes in proteins and protein complexes on a per-residue basis [see supporting online material (SOM)] (22). Traditionally, NMR studies were...
Protein Dynamics

relegated to studying proteins smaller than 20 to 30 kD. However, recent advances in NMR methodologies can now probe conformational and dynamic properties of protein complexes approaching 1 MD (23). Collectively, NMR data can derive information reflecting the ligand-binding energetics of a particular complex. For example, differences in protein conformation upon the addition of a small druglike molecule reflect enthalpic changes, whereas differences in dynamic properties indicate entropic changes (24).

Conformational changes in proteins labeled with $^{15}$N and/or $^{13}$C stable isotopes can be detected by two-dimensional heteronuclear single-quantum coherence (HSQC) spectroscopy, with extensions that allow applications to larger proteins (25). Upon ligand binding, cross peaks representing residues in or near binding sites will be perturbed, either by shifting locations or broadening out. These data are mapped onto a protein structure, providing a “fingerprint” and allowing easy differentiation between competitive and allosteric-site binders (Fig. 1). By the same principle, protein dynamics in the absence and presence of small-molecule ligands can be compared. This experiment is the basis for the well-established and widely used structure-activity relationship (SAR)–by–NMR technique (25), which combines NMR and fragment-based approaches for drug design and development. NMR can be used to quantitatively measure the binding affinities of ligands with submicromolar to millimolar dissociation constant values. An extension of the SAR-by-NMR technique that holds potential for semi–high-throughput ligand screening involves the simultaneous acquisition of multiple target protein spectra by differential labeling. NMR spectral editing techniques deconvolute the spectra to separate the data of the individual proteins, allowing determination of which, if any, targets interact with the ligand (26, 27).

A combination of NMR spectroscopy and x-ray crystallography showed how imatinib (Gleevec) allosterically inhibits the ABL tyrosine kinase associated with chronic myelogenous leukemia. Second-generation ABL inhibitors currently on the market include dasatinib (Sprycel) and nilotinib (Tasigna). Proliferation assays involving Bcr-ABL-expressing cells indicated imatinib median inhibitory concentration (IC$_{50}$) values of 260 nM, with higher potencies reported for nilotinib (13 nM) and dasatinib (0.8 nM) (28). Enzyme activity is regulated by a structural motif that places the catalytic residues in an orientation required for efficient substrate phosphorylation. This motif contains an $\alpha$ helix and two loops: the phosphate-binding (P) and activation (A) loops, with the A loop adopting two major conformers corresponding to the active and inactive states (29).

Although classified as competitive adenosine triphosphate inhibitors, x-ray crystallography studies of ABL-imatinib and ABL-nilotinib complexes indicate that ligand binding induces an allosteric reorientation of the A loop to its inactive state. Conversely, and counter to activity studies, complexes of ABL-dasatinib and two investigational compounds display the active conformation in their crystal structures (29). Recent NMR data confirm the x-ray crystallography data and suggest that the A loop of the protein is still conformationally dynamic. Corresponding residues within all the ABL-inhibitor complexes display peak broadening and indicate that dasatinib imparts enhanced backbone dynamics relative to imatinib-nilotinib and that it is able to sample both the active and inactive ABL loop conformations (29). This suggests that the major effect on enzyme

**Fig. 1.** (A) Shallow wells and transitional barriers of a dynamic free-energy landscape allow a macromolecule to sample multiple preexisting conformational states, corresponding to the catalytically active (green) and inactive (blue, red, yellow, and gray) forms. The global energy minimum shifts to favor the inactive conformation (red) when an inhibitor (cyan star) binds to an allosteric site. (B) The active (green) and inactive (red) conformations schematically represent a small enzyme, consisting of a flexible loop connecting two helices. Both conformations are in equilibrium while the enzyme is in the apo state. A native substrate (orange triangle) binds to the active site located between the two helices. Alternatively, a small molecule (cyan star) binds to a region within the flexible loop of the inactive conformation, allosterically inhibiting the enzyme. (C) Overlaid theoretical $^{1}H$-$^{15}N$-HSQC spectra display peaks corresponding to backbone amides of residues in selected regions of the enzyme, numbered 1 to 4. Green and pink peaks represent the apo active and inactive conformers (left); orange and cyan peaks represent the bound active and inactive conformers (right), respectively. As depicted, peak 1 of the active and inactive conformations is located in the same helix of both conformations and is superimposable (purple box), whereas peaks 2 to 4 correspond to regions within the flexible loop region. Upon native substrate binding at the active site, only peak 1 of the active conformation shifts to a new location (orange box). Similarly, only peak 2 of the inactive conformation (cyan box) is perturbed when a small-molecule inhibitor binds at an allosteric site.
activity is conformationally based. Future drug discovery efforts can benefit from the HSQC fingerprints of the active and inactive loop conformations, by identifying promising new leads that impart diagnostic spectral signatures.

In addition to quickly mapping ligand-binding–induced conformational changes of a macromolecule, NMR also detects disruptions in protein complexes by taking advantage of the overall dynamics of large oligomeric complexes. A protein that displays sharp resonances in its monomeric state would exhibit extensive peak broadening once it became part of a larger macromolecular complex. If a small molecule disrupts these complexes, the protein would exhibit an HSQC spectrum closely associated with its monomeric state (30). A major advantage of this technique is that it does not require protein resonance assignments. Additionally, these assays are able to identify which protein partner binds to the small molecule. If the small molecule strongly associates with one of the protein partners, the final HSQC spectrum also acts as a starting point for further SAR-by-NMR studies.

This dynamic property of protein complexes for detecting small-molecule ligands that disrupt protein-protein interactions was demonstrated with the well-studied p53-MDM2 complex (31). Activity of p53 is intimately involved with suppressing tumor growth and proliferation in a number of cancer types; unchecked p53-MDM2 binding results in the misregulation of p53 activity. Binding competition experiments were reported with nutlin-3 (SOM) (30), a member of the nutlin family that inhibits p53-MDM2 binding with an IC50 value of 90 nM (32). This affinity is comparable to that observed for p53-MDM2 binding as determined with the use of peptide analogs and surface plasmon resonance (33). The N-terminal domain of p53 displays a dramatic disorder-to-order transition. In the apo state, it is intrinsically unstructured, whereas in complex with MDM2, it folds into an α helix. Meanwhile, the apo form of MDM2 contains a short N-terminal “lid” region, which exists in slow exchange between a conformationally dynamic open (minor) state and a more structured helical closed (major) state closely associated with the p53-binding cleft of MDM2 (34). An examination of the backbone dynamics of the lid indicates higher conformational mobility in the p53-MDM2 dimer relative to the apo MDM2 and MDM2–nutlin-3 complex (34). Nutlin-3 does not conformationally trap an inactive state of either MDM2 or p53. However, these initial studies lay the groundwork for future drug discovery efforts, which may lead to compounds that trap either protein in an inactive state.

Protein–protein interactions involving cAMP response element–binding protein (CREB) and CREB-binding protein (CBP) also illustrate the use of NMR for screening small-molecule conformational traps in a more highly conformationally dynamic complex. CREB is involved with cellular signaling, and misregulation of its activity is associated with various neurological disorders and cancers, whereas CBP is classified as a coactivator protein. Interactions between the two proteins are governed by the KID domain of CREB and the KIX domain of CBP. The KID domain is unfolded in its apo state but forms two helices when bound to KIX (35). Similarly, the KIX domain exhibits lowly populated conformers in its apo state, becoming less dynamic upon binding to KID (36).

Previous inhibition studies primarily focused on short peptides that competitively associated with the shallow hydrophobic KID-binding cleft of KIX (37). However, NMR screening of 762 preselected small-molecule ligands demonstrated that protein–protein interactions of this complex can be regulated by trapping an inactive conformer (38). Mapping the HSQC spectral differences onto the structures indicated that two of these compounds bound to sites in the KIX domain that were distal to the KID-binding pocket. Residues of the KID-binding cleft display smaller mobilities upon complexation (33) and interactions onto the structures indicated that the KID-binding site resides on short peptides that competitively associate and cannot be displaced by the shallow hydrophobic KID-binding cleft (39). Along with the realization that biological macromolecules exist in binding free-energy landscapes (39) comes a myriad of opportunities for drug discovery. Target receptors that were biologically validated but then deemed undruggable are now more attractive. In some cases, the less tractable targets, such as complexes involving protein–protein interactions, can be reconsidered or, as in the case of the human herpesvirus proteases, even resurrected. The greater selectivity of these allosteric inhibitors we refer to as conformational traps could be of great benefit to compounds facing the gauntlet of factors, such as efficacy, pharmacokinetics, and toxicity, that result in the staggering attrition rate of current clinical lead compounds in the drug pipeline. Similarly, issues surrounding any drug lead such as sufficient affinity, ligand efficiency, binding free energy per atom, absorption, and permeability must be addressed. Integration of multiple methodologies such as NMR spectroscopy and computational modeling (40) to complement the current approaches of rational drug design is needed. This will substantially increase the chances of effectively hitting a given target to antagonize or agonize its activity.

References and Notes

11. C. J. Tsai, S. Kumar, B. Ma, R. Nussinov, Protein Sci. 8, 1181 (1999).
28. T. O’Hare et al., Cancer Res. 65, 4500 (2005).
41. This research was supported in part by grants from the NIH (grant RO1AI067423) and the HIV Accessory and Regulatory Complex Center (grant P50 GM082250). G.M.L. is a recipient of the 2007–2008 UCSF–Gladstone Institute for Virology & Immunology/Center for AIDS Research Clinical Science Pilot Award (grant P30-M012763). We also thank K. Dill, J. Gross, D. Hostetter, and T. Shahan for discussion and proofreading of this manuscript.

Supporting Online Material

www.sciencemag.org/cgi/content/full/324/5924/213/DC1

SOM Text

References

10.1126/science.1169378